From: Integrative network analysis identifies potential targets and drugs for ovarian cancer
Drug | Target | Titles of articles related to ovarian cancer treatment |
---|---|---|
Acetylcysteine | CHUK | N-acetylcysteine potentiates doxorubicin-induced ATM and p53 activation in ovarian cancer cells [24]. |
Acetylsalicylic acid | TP53, PRKAG1, NFKBIA | Aspirin inhibits growth of ovarian cancer by upregulating caspase-3 and downregulating bcl-2 [25]. |
Adalimumab | TNF | Â |
Adenosine triphosphate | ARAF, AKT1 | Â |
Afatinib | ERBB2, EGFR | Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1 [26]. |
Aminosalicylic acid | CHUK | Â |
Amrinone | TNF | Â |
Apremilast | TNF | Â |
Arsenic trioxide | MAPK1, MAPK3, AKT1 | Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line [27]. |
Becaplermin | PDGFRA | Â |
Bosutinib | MAP2K1, MAP2K2 | Ovarian Cancer Stem Cell Markers: Prognostic and Therapeutic Implications [28]. |
Captopril | MMP9 | Epithelial ovarian cancer: A feasible plan for adjunctive treatment using simultaneous acyclovir, ambrisentan, captopril, disulfiram, fluvoxamine-augmented ramelteon, icatibant, imiquimod peritoneal lavage, and plerixafor [29]. |
Carvedilol | HIFA1 | Cardiovascular complications of antiangiogenic therapy in ovarian cancer patients [30]. |
Celecoxib | PDPK1 | The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer [31]. |
Certolizumab pegol | TNF | Â |
Cetuximab | EGFR | Phase II Trial of Cetuximab and Carboplatin in Relapsed Platinum-Sensitive Ovarian Cancer and Evaluation of Epidermal Growth Factor Receptor Expression: A Gynecologic Oncology Group Study [32]. |
Chloroquine | TNF | Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagy [33]. |
Clenbuterol | TNF | Â |
Cobimetinib | MAP2K1 | Â |
Dabrafenib | RAF1 | Â |
Dasatinib | EPHA2 | Activity of the multikinase inhibitor dasatinib against ovarian cancer cells [34]. |
Epinephrine | TNF | Â |
Erlotinib | EGFR | Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review [35]. |
Etanercept | TNF | Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer [36]. |
Everolimus | MTOR | Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report [37]. |
Gefitinib | EGFR | Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells [38]. |
Glucosamine | TNF, MMP9 | Â |
Golimumab | TNF | Â |
Imatinib | PDGFRA | Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation [39]. |
Infliximab | TNF | Infliximab, a humanised anti-TNF-a monoclonal antibody, exhibits biological activity in the ovarian tumor microenvironment in patients [40]. |
Isoprenaline | PIK3R3, PIK3R2, MAPK1 | Targeted anti-vascular therapies for ovarian cancer: current evidence [41]. |
Isopropyl alcohol | TNF | Â |
Lapatinib | ERBB2, EGFR | A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study [32]. |
Lidocaine | EGFR | Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation [42]. |
Lithium | GSK3B | Lithium and inhibition of GSK3β as a potential therapy for serous ovarian cancer [43]. |
Marimastat | MMP9 | Marimastat (BB2516): Current status of development [44]. |
Mesalazine | CHUK | Â |
Minocycline | MMP9 | Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways [45]. |
Nadroparin | MYC | Â |
Necitumumab | EGFR | Â |
Osimertinib | EGFR | Â |
Panitumumab | EGFR | Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges [46]. |
Pazopanib | PDGFRA | Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer [47]. |
Pegademase bovine | GRB2 | Â |
Pertuzumab | ERBB2 | A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer [48]. |
Pimecrolimus | MTOR | Topical pimecrolimus inhibits high-dose UVB irradiation-induced epidermal Langerhans cell migration, via regulation of TNF-a and E-cadherin [49]. |
Pomalidomide | TNF | Â |
Ponatinib | PDGFRA | Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition [50]. |
Pranlukast | TNF | Â |
Pseudoephedrine | TNF | Â |
Regorafenib | EPHA2, RAF1, PDGFRA | 301P Interim Analysis of A Single-Arm Phase 2 Clinical Trial of Regorafenib in Patients with Epithelial Ovarian Cancer [51]. |
Sirolimus | MTOR | Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells [52]. |
Sorafenib | RAF1 | Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial [53]. |
Sucralfate | EGF | Â |
Sulfasalazine | CHUK | Sulfasalazine Inhibits IL-2 Expression in Ovarian Cancer Cells [54]. |
Sulindac | MAKP3 | The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 [55]. |
Sunitinib | PDGFRA | Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma [56]. |
Tamoxifen | PRKCZ, ESR1, PRKCI | The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer [57]. |
Temsirolimus | MTOR | Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8) [58]. |
Thalidomide | TNF | Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature [59]. |
Trametinib | MAP2K1, MAP2K2 | The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737 [60]. |
Trastuzumab | ERBB2, EGFR | Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics [61]. |
Trastuzumab emtansine | ERBB2 | Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression [62]. |
Tris | DCN | Synergism from Combinations of tris(benzimidazole) monochloroplatinum(II) Chloride with Capsaicin, Quercetin, Curcumin and Cisplatin in Human Ovarian Cancer Cell Lines [63]. |
Vandetanib | EGFR | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2 [64]. |
Vitamin c | EGLN3 | The Effect of Intravenous Vitamin C on Cancer- and Chemotherapy-Related Fatigue and Quality of Life [65]. |